{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:46:01Z","timestamp":1771357561178,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1552,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1365-2796.2011.02395.x","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T11:47:58Z","timestamp":1307101678000},"page":"281-290","source":"Crossref","is-referenced-by-count":34,"title":["The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events"],"prefix":"10.1111","volume":"270","author":[{"given":"H.","family":"Almroth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fengsrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Linde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rosenqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Englund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,2]]},"reference":[{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB1|cit1","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0002-9149(93)90511-A","article-title":"Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation","volume":"71","author":"Reimold","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1161\/01.CIR.82.6.1932","article-title":"Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation","volume":"82","author":"Juul-Moller","year":"1990","journal-title":"Circulation"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","volume":"321","author":"The Cardiac Arrhythmia Suppression Trial (CAST) Investigators","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/europace\/eul097","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"8","author":"Fuster","year":"2006","journal-title":"Europace"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/0002-9149(89)90017-9","article-title":"A biological approach to sudden cardiac death: structure, function and cause","volume":"63","author":"Myerburg","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(98)00297-6","article-title":"Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction","volume":"32","author":"Dries","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1023\/A:1011460631369","article-title":"Atrial fibrillation: a risk factor for increased mortality - an AVID registry analysis","volume":"5","author":"Wyse","year":"2001","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/eurheartj\/ehm308","article-title":"Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF)","volume":"28","author":"Friberg","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.80.6.1557","article-title":"Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group","volume":"80","author":"Anderson","year":"1989","journal-title":"Circulation"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0002-9149(91)90828-9","article-title":"Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter","volume":"68","author":"Crijns","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ahj.2007.08.033","article-title":"A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: a Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial","volume":"155","author":"Gulizia","year":"2008","journal-title":"Am Heart J"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0002-9149(91)90527-R","article-title":"Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group","volume":"67","author":"Pietersen","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/oxfordjournals.eurheartj.a059670","article-title":"Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects","volume":"11","author":"Sihm","year":"1990","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005344-198901000-00005","article-title":"Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation","volume":"13","author":"van Wijk","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"66A","DOI":"10.1016\/S0002-9149(97)89120-5","article-title":"Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation\/flutter. The Flecainide AF French Study Group","volume":"77","author":"Aliot","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB23|cit23","first-page":"51","article-title":"A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation","volume":"25","author":"Carunchio","year":"1995","journal-title":"G Ital Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/oxfordjournals.eurheartj.a060852","article-title":"Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group","volume":"16","author":"Chimienti","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"53A","DOI":"10.1016\/S0002-9149(97)89118-7","article-title":"Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation\/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group","volume":"77","author":"Naccarelli","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1055\/s-2008-1067903","article-title":"Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?","volume":"113","author":"Steinbeck","year":"1988","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0002-9149(89)90574-2","article-title":"Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter","volume":"64","author":"Van Gelder","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB28|cit28","first-page":"507","article-title":"Meta-analysis of flecainide safety in patients with supraventricular arrhythmias","volume":"52","author":"Wehling","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/europace\/eup119","article-title":"Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study","volume":"11","author":"Andersen","year":"2009","journal-title":"Europace"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"32E","DOI":"10.1016\/0002-9149(87)90199-8","article-title":"Risk factors for the development of proarrhythmic events","volume":"59","author":"Morganroth","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0735-1097(86)80190-5","article-title":"Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide","volume":"8","author":"Morganroth","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7326\/0003-4819-111-2-107","article-title":"Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation","volume":"111","author":"Falk","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \u201cpill-in-the-pocket\u201d approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0735-1097(10)80090-7","article-title":"Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group","volume":"17","author":"Pritchett","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1365-2796.2011.02395.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/01.CIR.0000077519.18416.43","article-title":"Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death","volume":"108","author":"Huikuri","year":"2003","journal-title":"Circulation"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2011.02395.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2796.2011.02395.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T06:20:21Z","timestamp":1625466021000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2011.02395.x"}},"subtitle":["Flecainide in AF patients: safety in clinical reality"],"short-title":[],"issued":{"date-parts":[[2011,6,2]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02395.x","relation":{},"ISSN":["0954-6820"],"issn-type":[{"value":"0954-6820","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,2]]}}}